Navigation Links
Alkermes Announces Positive Results from Phase 1/2 Clinical Study,of ALKS 29

Inc. Alkermes' pipeline includes extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases such as central nervous system disorders, addiction and diabetes. Alkermes' headquarters are in Cambridge, Massachusetts, and it operates research and manufacturing facilities in Massachusetts and Ohio.

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements about Alkermes' addiction portfolio, including its development activities for ALKS 29 and other proprietary product candidates. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and the company's business is subject to significant risk and uncertainties and there can be no assurance that its actual results will not differ materially from its expectations. These risks and uncertainties include, among others: whether future clinical studies of ALKS 29 will confirm previous results; whether the company will pursue continued development of ALKS 29 or other proprietary product candidates for the treatment of addiction, including alcohol dependence; whether the combination of the two agents tested will provide advantages over existing oral medications; whether the company will present data from the phase 1/2 study at a future medical meeting; and decisions by the FDA regarding ALKS 29 or other oral product candidates. For further information with respect to factors that could cause the company's actual results to differ materially from expectations, reference is made to the reports the company filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The company disclaims any intention or responsibility for updating forward
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/31/2015)... Weiss LLP is reporting that on July 13, 2015, the ... Bard, the manufacturer of Inferior vena cava (IVC) filters ... agency found at two of Bard,s facilities. Bard was previously ... during Inspectional Observations that occurred on November 18, 2014, through ... , location and on October 6, 2014, through November 25, ...
(Date:7/31/2015)... , July 31, 2015  Boston Children,s ... benefiting from 3D printing of their anatomy before ... life-threatening cerebrovascular malformations (abnormalities in the brain,s blood ... Reporting online today in the Journal of ... of 3D printing and synthetic resins to create ...
(Date:7/31/2015)... Scientific, Inc. (Nasdaq: SMLR ), a company that ... physician groups, today reported financial results for the second ... the second quarter of 2015, Semler reported continued progress ... over quarter revenue growth of 8%, and quarter over ... of 18%," said Doug Murphy-Chutorian, M.D., chief executive officer ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 33D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... Southern California-based philanthropy Free Wheelchair Mission has ... International,s annual giving catalog. Called "Relief in ... humanitarian outreach operations, supporting causes including hunger alleviation, ... The two international nonprofits have collaborated since 2005, ...
... , BAD HOMBURG, Germany and LACHEN, Switzerland, Oct. ... signed a License, Development and Supply Agreement regarding ... develop a HESylated recombinant protein. , Under the ... Technology to Octapharma. This technology platform is based ...
Cached Medicine Technology:OC-Based Charity Teams with International Relief Organization in Holiday Fundraising Drive 2Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein 2Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein 3
(Date:8/1/2015)... ... , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for ... by stepping off Springer Mountain and heading north. Since that day, Phil has hiked over ... was greeted by friends and family. He visited CCAR and left an inspirational message ...
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium in ... each year is the Super Bowl. In the two weeks that separate the conference championships ... venue. The 2016 Super Bowl game will mark the 50th time it has been held ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight On ... on October 3, 2015. The Ride to Fight On is a cycling fundraiser that ... Healthcare, The West Clinic and The University of Tennessee Health Science Center. A health ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Coco Libre announced ... judges, media, and VIPs at the 2015 Vans US Open of Surfing, July 25 ... that can claim “no added sugar” on the market, is a natural choice given ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique ... wedding cakes with custom designs, making life just a little bit sweeter ... wedding cakes for each customer who orders one. , The bakery provides a full ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... created an uptick in his business as more people find themselves either ... back. , ... Concord, CA (PRWEB) April 3, 2009 -- As economies ... play out for the young but booming medical tourism industry . ...
... As news emerged that Gov. Kathleen Sebelius, nomination ... postponed until the end of April, American Life ... Pat Roberts to reject the nomination.(Logo: ... Courtesy" -- the longstanding Senate tradition only confirming ...
... completion may boost patient compliance, outcomes, researchers say , , ... antibiotic called moxifloxacin in combination with other drugs could ... takes to cure patients with drug-treatable tuberculosis, according to ... result in patients failing to complete their drug therapy, ...
... Event highlights accomplishments of three highly recruited adapted sports ... rehabilitation and resource center Courage Center has had a ... in adapted sports such as wheelchair basketball and rugby. ... high school seniors will sign college letters of intent ...
... the release of the first long-range plan for tackling ... Americans each year. , Opportunities and Challenges in Digestive ... Diseases describes the impact of diseases ranging from foodborne ... priorities for research over the next 10 years. The ...
... Healthcare Holdings, Inc. announced today that it has agreed ... County Physicians Investment Network, LLC, which is owned primarily ... shareholders, and certain related parties of OC-PIN. The ... in May, 2007 against two of its former directors ...
Cached Medicine News:Health News:Economic Turmoil Creates Boom for Medical Tourism 2Health News:Economic Turmoil Creates Boom for Medical Tourism 3Health News:Economic Turmoil Creates Boom for Medical Tourism 4Health News:A.L.L. Calls on KS Senators to Stop Sebelius as Confirmation Postponed 2Health News:New Antibiotic Could Shorten TB Treatment 2Health News:Courage Center Hosts College Scholarship Signing Ceremony Thursday, April 9, 2009 2Health News:NIH releases the first research plan to reduce the burden of digestive diseases 2Health News:NIH releases the first research plan to reduce the burden of digestive diseases 3Health News:IHHI Settles Litigation With OC-PIN 2
For the qualitative determination of magnesium in serum....
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Medicine Products: